Cure SMA is pleased to announce the release of “Spotlight on SMA: The Spinal Muscular Atrophy Treatment Landscape,” the final supplement in a two-part series developed in collaboration with Neurology Reviews.
The goal of this partnership is to increase awareness of SMA amongst healthcare providers, including current clinical guidelines and the need for prompt diagnosis and treatment. This supplement discusses:
- The evolving SMA phenotype;
- Therapeutic strategies for SMA and the growing SMA drug pipeline;
- FDA approved therapies for SMA; and
- The recommended standard of care for SMA.
The supplement was be distributed as part of the Neurology Reviews’ Rare Neurological Disease Special Report to all subscribers of the publication, and is available online, free of cost at mdedge.com/SMATreatment.
Part 1 of the series, “Spotlight on SMA: The Urgent Need for Early Diagnosis in Spinal Muscular Atrophy” was published in December 2019 and is also available online. It includes resources from SMArt Moves, a disease awareness and education campaign launched by Cure SMA and the SMA Industry Collaboration to empower parents and healthcare professionals to promptly recognize and diagnose the early signs of SMA.
For more information, visit our “About SMA for Healthcare Providers” page.
About the SMA Industry Collaboration (SMA-IC)
The SMA-IC is a multi-faceted partnership that brings together pharmaceutical companies, Cure SMA, and other nonprofit organizations, to share information, ideas, and data. The Collaboration works together to address scientific, clinical, and regulatory topics that are critical to advancing drug development in SMA and will benefit the broader SMA community partners. It is currently comprised of our partners at Astellas, AveXis, Biogen, Cytokinetics, Genentech/Roche, and Scholar Rock.